Sarepta Therapeutics (AB3A) Financial Statements

0 Followers

Sarepta Therapeutics Financial Overview

Sarepta Therapeutics's market cap is currently CHF1.62B. The company's EPS TTM is CHF-1.44; its P/E ratio is -12.93; Sarepta Therapeutics is scheduled to report earnings on August 5, 2026, and the estimated EPS forecast is CHF0.06. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 2.20B	$ 1.90B	$ 1.24B	$ 933.01M	$ 701.89M
Gross Profit	$ 1.32B	$ 1.58B	$ 1.09B	$ 793.02M	$ 604.84M
Operating Income	$ -657.77M	$ 218.08M	$ -267.82M	$ -536.20M	$ -459.71M
EBITDA	$ -647.97M	$ 316.89M	$ -453.69M	$ -594.85M	$ -317.41M
Net Income	$ -713.41M	$ 235.24M	$ -535.98M	$ -703.49M	$ -418.78M
Balance Sheet
Cash & Short-Term Investments	$ 939.65M	$ 1.35B	$ 1.68B	$ 1.99B	$ 2.12B
Total Assets	$ 3.35B	$ 3.96B	$ 3.26B	$ 3.13B	$ 3.15B
Total Debt	$ 1.04B	$ 1.34B	$ 1.40B	$ 1.62B	$ 1.15B
Net Debt	$ 238.46M	$ 240.06M	$ 968.38M	$ 650.58M	$ -962.43M
Total Liabilities	$ 2.21B	$ 2.44B	$ 2.41B	$ 2.74B	$ 2.22B
Stockholders' Equity	$ 1.14B	$ 1.53B	$ 859.34M	$ 384.95M	$ 928.01M
Cash Flow
Free Cash Flow	$ -307.45M	$ -352.74M	$ -588.34M	$ -357.60M	$ -481.66M
Operating Cash Flow	$ -205.48M	$ -205.79M	$ -500.99M	$ -325.35M	$ -443.17M
Investing Cash Flow	$ 69.64M	$ 755.56M	$ -165.80M	$ -1.05B	$ 495.41M
Financing Cash Flow	$ -168.34M	$ 124.81M	$ 125.00M	$ 232.51M	$ 561.57M

Currency in USD

Sarepta Therapeutics Earnings and Revenue History

Income Statement >

Sarepta Therapeutics Debt to Assets

Balance Sheet >

Sarepta Therapeutics Cash Flow

Cash Flow >

Sarepta Therapeutics Forecast EPS vs Actual EPS

Earnings >